×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
BCLI – brainstorm cell therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
BCLI
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
03:11 am
bcli
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Medium
Report
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/14
04:37 pm
bcli
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Low
Report
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/14
04:30 pm
bcli
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
11/13
12:08 am
bcli
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/11
06:00 am
bcli
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
Low
Report
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing
10/30
06:00 am
bcli
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Medium
Report
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
10/28
06:00 am
bcli
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
Medium
Report
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting
10/9
02:01 am
bcli
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:41 pm
bcli
Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30
Medium
Report
Form 10-Q BRAINSTORM CELL THERAPEU For: Sep 30
11/14
04:35 pm
bcli
Form 8-K BRAINSTORM CELL THERAPEU For: Nov 14
Medium
Report
Form 8-K BRAINSTORM CELL THERAPEU For: Nov 14
11/14
03:25 pm
bcli
Form SC 13G BRAINSTORM CELL THERAPEU Filed by: ARMISTICE CAPITAL, LLC
Low
Report
Form SC 13G BRAINSTORM CELL THERAPEU Filed by: ARMISTICE CAPITAL, LLC
11/13
07:56 am
bcli
Form SC 13G BRAINSTORM CELL THERAPEU Filed by: Ruck Matthew J
Neutral
Report
Form SC 13G BRAINSTORM CELL THERAPEU Filed by: Ruck Matthew J
10/30
08:42 am
bcli
Form 8-K BRAINSTORM CELL THERAPEU For: Oct 29
Medium
Report
Form 8-K BRAINSTORM CELL THERAPEU For: Oct 29
10/2
08:00 am
bcli
Form 4 BRAINSTORM CELL THERAPEU For: Sep 30 Filed by: Lebovits Chaim
High
Report
Form 4 BRAINSTORM CELL THERAPEU For: Sep 30 Filed by: Lebovits Chaim
10/1
04:05 pm
bcli
Form 8-K BRAINSTORM CELL THERAPEU For: Sep 30
High
Report
Form 8-K BRAINSTORM CELL THERAPEU For: Sep 30
9/30
06:02 am
bcli
Form EFFECT BRAINSTORM CELL THERAPEU
Medium
Report
Form EFFECT BRAINSTORM CELL THERAPEU
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/14
Form 4 BRAINSTORM CELL THERAPEU For: Dec 12 Filed by: TAUB MALCOLM S
22.7%
2/11 BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS 15.0%
3/6 BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share 13.2%
4/3 Form 8-K BRAINSTORM CELL THERAPEU For: Apr 01 6.2%
4/29 BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update 5.6%
4/7 Form 3 BRAINSTORM CELL THERAPEU For: Mar 30 Filed by: Abbhi Sankesh 4.3%
11/20 BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology 4.0%
11/4 Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics [Seeking Alpha] 3.5%
8/13 BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update 3.3%
8/9 Form D BRAINSTORM CELL THERAPEU 3.1%
2/11 BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS 15.0%
3/6 BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share 13.2%
4/3 Form 8-K BRAINSTORM CELL THERAPEU For: Apr 01 6.2%
4/29 BrainStorm-Cell Therapeutics to Announce First Quarter Financial Results and Provide a Corporate Update 5.6%
4/7 Form 3 BRAINSTORM CELL THERAPEU For: Mar 30 Filed by: Abbhi Sankesh 4.3%
11/20 BrainStorm Cell Therapeutics Announces Publication of NurOwn® ALS Phase 2 Randomized Clinical Trial Data in Neurology 4.0%
11/4 Interview With Chaim Lebovits, CEO Of Brainstorm Cell Therapeutics [Seeking Alpha] 3.5%
8/13 BrainStorm Announces Financial Results for the Second Quarter of 2019 and Provides a Corporate Update 3.3%
8/9 Form D BRAINSTORM CELL THERAPEU 3.1%
TOP News Decliners
3/16
BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19
-24.4%
2/27 Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial -14.4%
3/6 Form 4 BRAINSTORM CELL THERAPEU For: Mar 06 Filed by: Kern Ralph Dr. -14.3%
3/18 Form SC 13G BRAINSTORM CELL THERAPEU Filed by: Abbhi Investments, LLC -11.8%
2/13 Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -9.5%
8/2 Form 8-K BRAINSTORM CELL THERAPEU For: Aug 02 -5.4%
4/3 BrainStorm Cell +4% premarket on $1.5M grant [Seeking Alpha] -5.3%
11/18 Does Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Have A High Beta? [Yahoo! Finance News] -4.9%
4/1 David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer -4.7%
11/14 Q3/2019 9/30/2019 EPS -0.250 ZacksConsensus -0.160 ActVsEst (0.090) - Miss -4.6%
2/27 Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial -14.4%
3/6 Form 4 BRAINSTORM CELL THERAPEU For: Mar 06 Filed by: Kern Ralph Dr. -14.3%
3/18 Form SC 13G BRAINSTORM CELL THERAPEU Filed by: Abbhi Investments, LLC -11.8%
2/13 Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -9.5%
8/2 Form 8-K BRAINSTORM CELL THERAPEU For: Aug 02 -5.4%
4/3 BrainStorm Cell +4% premarket on $1.5M grant [Seeking Alpha] -5.3%
11/18 Does Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Have A High Beta? [Yahoo! Finance News] -4.9%
4/1 David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer -4.7%
11/14 Q3/2019 9/30/2019 EPS -0.250 ZacksConsensus -0.160 ActVsEst (0.090) - Miss -4.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: